



18th November 2008

PRESS RELEASE

FURTHER SIGNIFICANT SIGNS OF CHANGE AS IMPEDIMED'S L-DEX™ TECHNOLOGY IS ADOPTED IN THE NSW BREAST CANCER INSTITUTE

In a recent media release, the NSW Breast Cancer Institute (BCI) announced "an innovative lymphoedema screening program using Bioimpedance Spectroscopy to monitor women before surgery and during the first two years after surgery to detect and treat early stages of lymphoedema and prevent long-term severe lymphoedema symptoms."

ImpediMed is delighted that a prestigious institution like the NSW BCI has recognised the benefits of using the L-Dex™ approach to aid their health professionals in the pre-operative care of breast cancer patients for the early clinical assessment and prevention of lymphoedema.

ImpediMed's CEO Greg Brown commented that "The use of L-Dex™ technology at the NSW BCI and other leading centres around the world represents an ongoing emergence of a new clinical standard of care for medical professionals in their management of breast cancer patients in an attempt to prevent lymphoedema. It is particularly gratifying to see just how Australian medical care is on the leading edge of change. It is truly a pro-active approach to medicine and demonstrates how the Australian healthcare system is very focused on addressing all the needs of breast cancer patients from day one. The NSW BCI is well recognised, and having such a reputable institute using our technology for this pro-active care model is both exciting and influential in changing medical practice globally."

ENDS

For further information contact:

Greg Brown
Stephanie Paul

Impedimed CEO
Phillips Group

+61-7-3860-3700
+61-7-3230-5000 or +61-418-753-062

1/2

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.